Nucleoside analogue inhibitor of human immuno-deficiency virus (HIV) reverse transcriptase. Used as an anti-HIV drug.
a nucleoside reverse transcriptase inhibitor that is very effective in combination with zidovudine in treating AIDS and HIV
a NUCLEOSIDE ANALOG from GlaxoSmithKline with anti-HIV and anti-HEPATITIS B activity. Most common SIDE EFFECTS are nausea, headache, fatigue, diarrhea and ANEMIA.
an antiviral drug used to prevent the spread of HIV.
Indications: Treatment of HIV infection in combination with other agents. Also has activity against hepatitis B virus. Contraindications: Known hypersensitivity. Dosage: 150 mg po bid. Also available as Combivir, a fixed dose combination of ZDV 300 mg with 3TC 150 mg; and Trizivir, a fixed dose combination of ZDV 300 mg, 3TC 150 mg, and abacavir 300 mg. Toxicity: Uncommon. Headache, gastrointestinal intolerance, and insomnia have been reported. Pregnancy category C.
An oral nucleoside analogue drug that interferes with the replication of the hepatitis B virus (e.g. it can slow down or stop the virus from reproducing). It was the second drug approved for chronic hepatitis B in December 1998. Available for both adults and children.
A nucleoside reverse transcriptase inhibitor first approved by FDA in 1995 and used in combination with other antiretroviral agents for adults, adolescents, and children.
(3TC) Nucleoside analogue with anti-HIV and anti-hepatitis B activity.
Nucleoside reverse transcriptase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV. Also called 3TC. Generic name for Epivir®.
A nucleoside analogue drug, in the same family as AZT, that is used as an antiretroviral to treat HIV disease.
Lamivudine (2',3'-dideoxy-3'-thiacytidine, 3TC) is a potent reverse transcriptase inhibitor of the class nucleoside analog reverse transcriptase inhibitor (NARTI).
